A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years

Inclusion Criteria:

- Male or female subjects aged 7-11 years (both inclusive) at the time of signing
informed consent

- Tanner stage 1 (including subjects with premature adrenarche) at the time of signing
informed consent

- BMI (body mass index) corresponding to above or equal to 30 kg/m^2 for adults by
international cut-off points (Cole et al 2000)1 and BMI below or equal to 45 kg/m^2 as
well as BMI above or equal to 95th percentile for age and gender

Exclusion Criteria:

- Subjects with secondary causes of childhood obesity (i.e., hypothalamic, genetic or
endocrine causes)

- Subjects with confirmed bulimia nervosa disorder

- Diagnosis of type 1 diabetes mellitus or type 2 diabetes mellitus as defined by
glycosylated haemoglobin (HbA1C) Above or equal to 6.5 %

- History of pancreatitis (acute or chronic)

- Presence of severe co-morbidities as judged by the investigator

- Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or medullary
thyroid carcinoma (MTC)

- History of major depressive disorder within 2 years before randomisation